Calquence: Data from P3 ESCALADE trial (NCT04529772) for DLBCL post 2026 (AstraZeneca) - Jul 29, 2025 - H1 & Q2 2025 Results: Data from P2 TrAVeRse trial (NCT05951959) in combination with venetoclax and rituximab for treatment-naïve MCL post 2026
P2 data • P3 data • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Mantle Cell Lymphoma • Oncology
|